Thrombin generation and cell-dependent hypercoagulability in sickle cell disease

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 10, 2016, Pages 1941-1952

  Whelihan, M F ^a   Lim, M Y ^a   Mooberry, M J ^a   Piegore, M G ^a   Ilich, A ^a   Wogu, A ^b   Cai, J ^b   Monroe, D M ^a   Ataga, K I ^a   Mann, K G ^c   Key, N S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c UNIVERSITY OF VERMONT   (United States)

Author keywords

anemia; erythrocyte; phosphatidylserine; protein S; sickle cell; thrombin

Indexed keywords

ACTIVATED PROTEIN C; PHOSPHATIDYLSERINE; PROTEIN C; PROTEIN S; THROMBIN; THROMBOMODULIN; ANTITHROMBIN III; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; PROTHROMBIN; THBD PROTEIN, HUMAN;

ADULT; ANTICOAGULATION; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SYNTHESIS; ERYTHROCYTE; FEMALE; HUMAN; HUMAN CELL; HYPERCOAGULABILITY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN S DEFICIENCY; SICKLE CELL ANEMIA; STEADY STATE; AFRICAN AMERICAN; BETA THALASSEMIA; BIOSYNTHESIS; BLOOD; BLOOD CLOTTING; CASE CONTROL STUDY; CHEMISTRY; COHORT ANALYSIS; COMPLICATION; CYTOLOGY; METABOLISM; PHYSIOLOGY; THROMBOCYTE; THROMBOPHILIA; THROMBOSIS; YOUNG ADULT;

ADULT; AFRICAN AMERICANS; ANEMIA, SICKLE CELL; ANTITHROMBIN III; BETA-THALASSEMIA; BLOOD COAGULATION; BLOOD PLATELETS; CASE-CONTROL STUDIES; COHORT STUDIES; ERYTHROCYTES; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; MALE; PHOSPHATIDYLSERINES; PROTEIN S; PROTEIN S DEFICIENCY; PROTHROMBIN; THROMBIN; THROMBOMODULIN; THROMBOPHILIA; THROMBOSIS; YOUNG ADULT;

EID: 84984677889     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13416     Document Type: Article

References (50)

1. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330: 1639–44.
2. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet 2010; 376: 2018–31.
3. Manwani D, Frenette PS. Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood 2013; 122: 3892–8.
4. Kato GJ, Hebbel RP, Steinberg MH, Gladwin MT. Vasculopathy in sickle cell disease: biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol 2009; 84: 618–25.
5. Pauling L, Itano HA, Singer SJ, Wells IC. Sickle cell anemia, a molecular disease. Science 1949; 109: 443.
6. Ingram VM. Abnormal human haemoglobins. III. The chemical difference between normal and sickle cell haemoglobins. Biochim Biophys Acta 1959; 36: 402–11.
7. Frenette PS, Atweh GF. Sickle cell disease: old discoveries, new concepts, and future promise. J Clin Invest 2007; 117: 850–8.
8. Hebbel RP, Schwartz RS, Mohandas N. The adhesive sickle erythrocyte: cause and consequence of abnormal interactions with endothelium, monocytes/macrophages and model membranes. Clin Haemat 1985; 14: 141–61.
9. Hebbel RP. Beyond hemoglobin polymerization: the red blood cell membrane and sickle disease pathophysiology. Blood 1991; 77: 214–37.
10. Graca-Souza AV, Arruda MA, de Freitas MS, Barja-Fidalgo C, Oliveira PL. Neutrophil activation by heme: implications for inflammatory processes. Blood 2002; 99: 4160–5.
11. Hebbel RP. Adhesion of sickle red cells to endothelium: myths and future directions. Transfus Clin Biol 2008; 15: 14–8.
12. Porto BN, Alves LS, Fernandez PL, Dutra TP, Figueiredo RT, Graca-Souza AV, Bozza MT. Heme induces neutrophil migration and reactive oxygen species generation through signaling pathways characteristic of chemotactic receptors. J Biol Chem 2007; 282: 24430–6.
13. Figueiredo RT, Fernandez PL, Mourao-Sa DS, Porto BN, Dutra FF, Alves LS, Oliveira MF, Oliveira PL, Graca-Souza AV, Bozza MT. Characterization of heme as activator of Toll-like receptor 4. J Biol Chem 2007; 282: 20221–9.
14. Setty BN, Rao AK, Stuart MJ. Thrombophilia in sickle cell disease: the red cell connection. Blood 2001; 98: 3228–33.
15. Ataga KI, Brittain JE, Desai P, May R, Jones S, Delaney J, Strayhorn D, Hinderliter A, Key NS. Association of coagulation activation with clinical complications in sickle cell disease. PLoS ONE 2012; 7: e29786.
16. Sparkenbaugh E, Pawlinski R. Interplay between coagulation and vascular inflammation in sickle cell disease. Br J Haematol 2013; 162: 3–14.
17. Chantrathammachart P, Mackman N, Sparkenbaugh E, Wang JG, Parise LV, Kirchhofer D, Key NS, Pawlinski R. Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease. Blood 2012; 120: 636–46.
18. Arumugam PI, Mullins ES, Shanmukhappa SK, Monia BP, Loberg A, Shaw MA, Rizvi T, Wansapura J, Degen JL, Malik P. Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice. Blood 2015; 126: 1844–55.
19. Ataga KI, Key NS. Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology Am Soc Hematol Educ Program. 2007; 91–6.
20. Tomer A, Harker LA, Kasey S, Eckman JR. Thrombogenesis in sickle cell disease. J Lab Clin Med 2001; 137: 398–407.
21. Whelihan MF, Lim MY, Key NS. Red blood cells and thrombin generation in sickle cell disease. Thromb Res 2014; 133(Suppl. 1): S52–3.
22. Lim MY, Ataga KI, Key NS. Hemostatic abnormalities in sickle cell disease. Curr Opin Hematol 2013; 20: 472–7.
23. Whelihan MF, Zachary V, Orfeo T, Mann KG. Prothrombin activation in blood coagulation: the erythrocyte contribution to thrombin generation. Blood 2012; 120: 3837–45.
24. Whelihan MF, Mooberry MJ, Zachary V, Bradford RL, Ataga KI, Mann KG, Key NS. The contribution of red blood cells to thrombin generation in sickle cell disease: meizothrombin generation on sickled red blood cells. J Thromb Haemost 2013.
25. Gordon EM, Klein BL, Berman BW, Strandjord SE, Simon JE, Coccia PF. Reduction of contact factors in sickle cell disease. J Pediatr 1985; 106: 427–30.
26. Miller RL, Verma PS, Adams RG. Studies of the kallikrein-kinin system in patients with sickle cell anemia. J Natl Med Assoc 1983; 75: 551–6.
27. Verma PS, Adams RG, Miller RL. Reduced plasma kininogen concentration during sickle cell crisis. Res Commun Chem Pathol Pharmacol 1983; 41: 313–22.
28. Mayer LD, Hope MJ, Cullis PR. Vesicles of variable sizes produced by a rapid extrusion procedure. Biochim Biophys Acta 1986; 858: 161–8.
29. Barenholz Y, Gibbes D, Litman BJ, Goll J, Thompson TE, Carlson RD. A simple method for the preparation of homogeneous phospholipid vesicles. Biochemistry 1977; 16: 2806–10.
30. Lawson JH, Krishnaswamy S, Butenas S, Mann KG. Extrinsic pathway proteolytic activity. Methods Enzymol 1993; 222: 177–95.
31. Cawthern KM, van‘t Veer C, Lock JB, DiLorenzo ME, Branda RF, Mann KG. Blood coagulation in hemophilia A and hemophilia C. Blood 1998; 91: 4581–92.
32. Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002; 100: 148–52.
33. Kessels H, Willems G, Hemker HC. Analysis of thrombin generation in plasma. Comput Biol Med 1994; 24: 277–88.
34. Hemker HC, Wielders S, Kessels H, Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993; 70: 617–24.
35. Singer ST, Ataga KI. Hypercoagulability in sickle cell disease and beta-thalassemia. Curr Mol Med 2008; 8: 639–45.
36. van Beers EJ, Spronk HM, Ten Cate H, Duits AJ, Brandjes DP, van Esser JW, Biemond BJ, Schnog JB, Group CS. No association of the hypercoagulable state with sickle cell disease related pulmonary hypertension. Haematologica 2008; 93: e42–4.
37. Westerman MP, Green D, Gilman-Sachs A, Beaman K, Freels S, Boggio L, Allen S, Zuckerman L, Schlegel R, Williamson P. Antiphospholipid antibodies, proteins C and S, and coagulation changes in sickle cell disease. J Lab Clin Med 1999; 134: 352–62.
38. el-Hazmi MA, Warsy AS, Bahakim H. Blood proteins C and S in sickle cell disease. Acta Haematol 1993; 90: 114–9.
39. Francis RB Jr. Protein S deficiency in sickle cell anemia. J Lab Clin Med 1988; 111: 571–6.
40. Nelsestuen GL, Kisiel W, Di Scipio RG. Interaction of vitamin K dependent proteins with membranes. Biochemistry 1978; 17: 2134–8.
41. Mankelow TJ, Griffiths RE, Trompeter S, Flatt JF, Cogan NM, Massey EJ, Anstee DJ. Autophagic vesicles on mature human reticulocytes explain phosphatidylserine-positive red cells in sickle cell disease. Blood 2015; 126: 1831–4.
42. Stuart MJ, Setty BN. Hemostatic alterations in sickle cell disease: relationships to disease pathophysiology. Pediatr Pathol Mol Med 2001; 20: 27–46.
43. Ataga KI, Moore CG, Hillery CA, Jones S, Whinna HC, Strayhorn D, Sohier C, Hinderliter A, Parise LV, Orringer EP. Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica 2008; 93: 20–6.
44. Butenas S, Branda RF, van't Veer C, Cawthern KM, Mann KG. Platelets and phospholipids in tissue factor-initiated thrombin generation. Thromb Haemost 2001; 86: 660–7.
45. de Jong K, Larkin SK, Styles LA, Bookchin RM, Kuypers FA. Characterization of the phosphatidylserine-exposing subpopulation of sickle cells. Blood 2001; 98: 860–7.
46. Yasin Z, Witting S, Palascak MB, Joiner CH, Rucknagel DL, Franco RS. Phosphatidylserine externalization in sickle red blood cells: associations with cell age, density, and hemoglobin F. Blood 2003; 102: 365–70.
47. Koshiar RL, Somajo S, Norstrom E, Dahlback B. Erythrocyte-derived microparticles supporting activated protein C-mediated regulation of blood coagulation. PLoS ONE 2014; 9: e104200.
48. van der Meer FJ, Koster T, Vandenbroucke JP, Briet E, Rosendaal FR. The Leiden Thrombophilia Study (LETS). Thromb Haemost 1997; 78: 631–5.
49. Dasgupta SK, Guchhait P, Thiagarajan P. Lactadherin binding and phosphatidylserine expression on cell surface-comparison with annexin A5. Transl Res 2006; 148: 19–25.
50. McCurdy PR, Sherman AS. Irreversibly sickled cells and red cell survival in sickle cell anemia: a study with both DF32P and 51CR. Am J Med 1978; 64: 253–8.